
AVROBIO AVRO
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
AVROBIO Betriebsaufwand 2011-2026 | AVRO
Betriebsaufwand Jährlich AVROBIO
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.7 M | 105 M | 119 M | 120 M | 75.8 M | 46.2 M | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 120 M | 46.2 M | 89.7 M |
Betriebsaufwand Vierteljährlich AVROBIO
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | 22.3 M | 18.3 M | - | 19.6 M | 11.4 M | 13 M | - | 10.1 M | 10.6 M | 25.2 M | - | 23 M | 27.8 M | 29.4 M | - | 32.6 M | 31.4 M | 26.9 M | - | 36.7 M | 28.9 M | 26.6 M | - | 18.1 M | 16.6 M | 17.7 M | - | 12.2 M | 9.55 M | 7.79 M | - | 6.37 M | 2.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 36.7 M | 2.54 M | 19.5 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
248 M | $ 7.4 | -2.25 % | $ 200 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Amarin Corporation plc
AMRN
|
233 M | $ 15.11 | 0.6 % | $ 6.16 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 0.83 | -1.14 % | $ 4.53 M | ||
|
AlloVir
ALVR
|
65.4 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Aptose Biosciences
APTO
|
26.3 M | - | -45.71 % | $ 1.2 M | ||
|
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.53 | 0.56 % | $ 8.49 B | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
209 M | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 221.49 | - | $ 5 B | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Brickell Biotech
BBI
|
14.4 M | - | -5.38 % | $ 6.06 M | ||
|
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | ||
|
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Bristol-Myers Squibb Company
BMY
|
12.2 B | $ 59.93 | -1.53 % | $ 122 B | ||
|
BioNTech SE
BNTX
|
512 M | $ 109.38 | - | $ 27.2 B | ||
|
Athersys
ATHX
|
79.8 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.43 | - | $ 365 M | ||
|
Amneal Pharmaceuticals
AMRX
|
539 M | $ 14.7 | - | $ 4.54 B | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 9.13 | - | $ 1.49 B | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.27 | -1.73 % | $ 14.3 M |